Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Featured review: Emerging roles of telomeric chromatin alterations in cancer

New Content ItemTelomeres, the nucleoprotein structures that cap the ends of eukaryotic chromosomes, play important and multiple roles in tumorigenesis. Functional telomeres need the establishment of a protective chromatin structure based on the interplay between the specific complex named shelterin and a tight nucleosomal organization. Telomere shortening in duplicating somatic cells leads eventually to the destabilization of the telomere capping structure and to the activation of a DNA damage response (DDR) signaling. The final outcome of this process is cell replicative senescence, which constitute a protective barrier against unlimited proliferation. Cells that can bypass senescence checkpoint continue to divide until a second replicative checkpoint, crisis, characterized by chromosome fusions and rearrangements leading to massive cell death by apoptosis. During crisis telomere dysfunctions can either inhibit cell replication or favor tumorigenesis by the accumulation of chromosomal rearrangements and neoplastic mutations. The acquirement of a telomere maintenance mechanism allows fixing the aberrant phenotype, and gives the neoplastic cell unlimited replicative potential, one of the main hallmarks of cancer.

Despite the crucial role that telomeres play in cancer development, little is known about the epigenetic alterations of telomeric chromatin that affect telomere protection and are associated with tumorigenesis.

In this review, the authors discuss the current knowledge on the role of telomeric chromatin in neoplastic transformation, with a particular focus on H3.3 mutations in alternative lengthening of telomeres (ALT) cancers and sirtuin deacetylases dysfunctions.

Click here to access the full article. 

Click here to access all of the reviews published to date in Journal of Experimental & Clinical Cancer Research.

Aims and scope

Journal of Experimental & Clinical Cancer Research is an online peer-reviewed journal that provides a high-quality forum for all aspects of basic, clinical and translational work in oncology.

Please click here to read more.


Mauro Castelli, Regina Elena National Cancer Institute, Italy

If you would like to contact Journal of Experimental & Clinical Cancer Research, please send an email to:​​​​​​​


Call for Papers: Hypoxia and Tumors

Hypoxia and Tumors © royaltystockphoto / FotoliaJournal of Experimental & Clinical Cancer Research is delighted to announce the launch of a new thematic series covering the hot topic of Hypoxia and Tumors.

The Special Issue will accept Research Articles and Reviews regarding the latest highlights on the role of hypoxia in all aspects of tumor progression, including therapy resistance and metastases. Submit here.

Submission opens: 1st December 2019
Submission deadline: 30th June 2020

Click here to view this collection. Click here to access all thematic series published to date in Journal of Experimental & Clinical Cancer Research.

Celebrating the 10th anniversary partnership with BMC

JECCR 10 years​​​​​​​2018 marks the 10th anniversary of the partnership between the Journal of Experimental & Clinical Cancer Research and BMC.

Over the past decade, the journal has established itself among some of the top Oncology titles in Journal Citation Reports. Click here to look back at some of the journal’s milestone achievements and best content from the past 10 years.

Reviewer Acknowledgement and New Recruitment

© Syda Productions /

The Editor-in-Chief of Journal of Experimental & Clinical Cancer Research would like to thank all of our reviewers who have contributed to the journal and is looking for new reviewers to assess manuscripts. For consideration, please send your CV with keywords and expertise to

Archival content

Journal of Experimental & Clinical Cancer Research has been publishing since 1982.  Prior to publishing with BioMed Central from 2008, Journal of Experimental & Clinical Cancer Research was published in print.  For enquiries about previous content, please contact us on:


Annual Journal Metrics